We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

98 hedge funds and large institutions have $85.5M invested in Endocyte, Inc. Common Stock in 2015 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 38 increasing their positions, 25 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 25

0% more funds holding

Funds holding: 9898 (0)

0% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 9

22% less capital invested

Capital invested by funds: $109M → $85.5M (-$23.5M)

27% less call options, than puts

Call options by funds: $936K | Put options by funds: $1.28M

Holders
98
Holders Change
Holders Change %
0%
% of All Funds
2.64%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
38
Reduced
25
Closed
9
Calls
$936K
Puts
$1.28M
Net Calls
-$342K
Net Calls Change
+$148K
Name Holding Trade Value Shares
Change
Change in
Stake
UBS AM
51
UBS AM
Illinois
$176K
1SB
52
1ST Source Bank
Indiana
$171K
Citadel Advisors
53
Citadel Advisors
Florida
$162K +$82K +13,666 +78%
Capital Fund Management (CFM)
54
Capital Fund Management (CFM)
France
$153K +$177K +29,435 New
VKH
55
Virtu KCG Holdings
New York
$149K +$172K +28,620 New
LCM
56
Leisure Capital Management
California
$145K +$9.88K +1,648 +6%
ARTA
57
A.R.T. Advisors
New York
$143K -$22.2K -3,700 -12%
Goldman Sachs
58
Goldman Sachs
New York
$138K +$8.52K +1,420 +6%
BA
59
BlackRock Advisors
Delaware
$129K +$9.44K +1,573 +7%
Susquehanna International Group
60
Susquehanna International Group
Pennsylvania
$128K -$976K -162,680 -87%
AllianceBernstein
61
AllianceBernstein
Tennessee
$125K +$21K +3,500 +17%
VOYA Investment Management
62
VOYA Investment Management
Georgia
$120K
AIG
63
American International Group
New York
$114K -$7.86K -1,310 -6%
DekaBank Deutsche Girozentrale
64
DekaBank Deutsche Girozentrale
Germany
$105K +$3K +500 +3%
Invesco
65
Invesco
Georgia
$105K +$121K +20,232 New
Citigroup
66
Citigroup
New York
$96K +$53.9K +8,984 +95%
YCM
67
Yakira Capital Management
Connecticut
$74K
Group One Trading
68
Group One Trading
Illinois
$70K +$80.5K +13,427 New
Barclays
69
Barclays
United Kingdom
$68K -$23.6K -3,937 -23%
EMG
70
Ellington Management Group
Connecticut
$65K +$75.6K +12,612 New
CCMH
71
Cornerstone Capital Management Holdings
New York
$61K -$47.4K -7,900 -40%
TC
72
TFS Capital
Pennsylvania
$57K -$220K -36,705 -77%
Janney Montgomery Scott
73
Janney Montgomery Scott
Pennsylvania
$53.7K +$62.1K +10,348 New
Legal & General Group
74
Legal & General Group
United Kingdom
$36K
TRCT
75
Tower Research Capital (TRC)
New York
$35K +$39.7K +6,618 New

ECYT Hedge Fund Activity: Q2 2015 in Review

98 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2015, worth a combined $85.5M — down 22% from $109M a quarter earlier.

Fund positioning in ECYT was balanced in Q2 2015: 9 funds opened new positions, 9 closed out, 38 added to existing stakes and 25 trimmed.

The largest buyer was Royal Bank of Canada, adding an estimated $670K. The largest seller was Fidelity Investments, cutting an estimated $6.61M.

  • 98 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2015, unchanged from Q1 2015.
  • Funds reported $85.5M of Endocyte, Inc. Common Stock stock for Q2 2015, down 22% quarter-over-quarter.
  • 9 funds opened new Endocyte, Inc. Common Stock positions in Q2 2015 and 9 closed out, a net change of 0 holders.
  • The largest Endocyte, Inc. Common Stock buyer in Q2 2015 was Royal Bank of Canada, an estimated $670K added.
  • The largest Endocyte, Inc. Common Stock seller in Q2 2015 was Fidelity Investments, an estimated $6.61M sold.

Based on aggregated 13F filings for Q2 2015.